Targeting NKG2DLs with an ADCC enhanced fusion protein for induction of NK cell reactivity against ovarian cancer.

ABSTRACT: Ligands for the activating immune receptor NKG2D (NKG2DLs) are frequently overexpressed on malignant cells while largely absent in healthy tissues. Elevated expression of various NKG2DLs has been reported in ovarian cancer, one of the most lethal gynecologic malignancies due to chemoresistance and relapse. Despite the advent of monoclonal antibodies (mAbs) in cancer therapy, patients with ovarian cancer have yet to benefit from this treatment modality. Natural killer (NK) cells play a crucial role in the efficacy of antitumor mAbs by mediating antibody-dependent cellular cytotoxicity (ADCC). Strategies to enhance ADCC often involve Fc region modifications to improve CD16 binding and NK cell activation.The tumor-associated expression of NKG2DLs was exploited by developing an Fc-optimized NK

SUBMITTER: Hagelstein I 

PROVIDER: S-EPMC12906047 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature